CERNER CORP's gross profit margin for the second quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. CERNER CORP is extremely liquid. Currently, the Quick Ratio is 2.38 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 10.46% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY14||Q2 FY13|
|Net Sales ($mil)||851.76||707.56|
|Net Income ($mil)||129.03||112.91|
|Balance Sheet||Q2 FY14||Q2 FY13|
|Cash & Equiv. ($mil)||988.79||969.52|
|Total Assets ($mil)||4265.28||3843.94|
|Total Debt ($mil)||155.37||181.9|
|Profitability||Q2 FY14||Q2 FY13|
|Gross Profit Margin||46.13||48.08|
|Return on Assets||9.93||11.28|
|Return on Equity||13.0||14.69|
|Debt||Q2 FY14||Q2 FY13|
|Share Data||Q2 FY14||Q2 FY13|
|Shares outstanding (mil)||341.01||343.03|
|Div / share||0.0||0.0|
|Book value / share||9.56||8.6|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1781382.0||2071668.0|
BUY. The current P/E ratio indicates a significant discount compared to an average of 246.49 for the Health Care Technology industry and a significant premium compared to the S&P 500 average of 19.49. For additional comparison, its price-to-book ratio of 6.12 indicates a significant premium versus the S&P 500 average of 2.70 and a discount versus the industry average of 6.47. The current price-to-sales ratio is well above the S&P 500 average and above the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, CERNER CORP proves to trade at a discount to investment alternatives within the industry.
|CERN 48.35||Peers 246.49||CERN 28.24||Peers 31.19|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
CERN is trading at a significant discount to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CERN is trading at a valuation on par to its peers.
|CERN 30.00||Peers 43.67||CERN 1.03||Peers 1.41|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
CERN is trading at a discount to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
CERN trades at a significant discount to its peers.
|CERN 6.12||Peers 6.47||CERN -1.23||Peers 147.26|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CERN is trading at a valuation on par with its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CERN is expected to significantly trail its peers on the basis of its earnings growth rate.
|CERN 6.31||Peers 6.06||CERN 13.88||Peers 15.97|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CERN is trading at a valuation on par with its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CERN trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV